BusinessBioCorRx Selects Covance for Non-Clinical Studies, Announces the Addition of Dr. Bal S. Brar to its Drug Development Team, Plans Pre-IND Meeting with FDABy Nasdaq OMXNov 28, 2016, 11:00 AM UTC
